As academics closely involved in UK biobanking, we welcome the suggestions made in The Lancet Oncology by Robert Coleman and colleagues 1 to develop guidelines to make the transfer of human tissue samples collected from trials into biobanks a more streamlined and transparent process. Patient-derived material and data are a valuable resource for contemporary biomedical research. Tissue from trials is especially valued due to the well-defined population and rigour of patient sampling and data curation.
